Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., Andrews, J. A., Babu, S., Benatar, M., McDermott, C. J., Cochrane, T., Chary, S., Chew, S., Zhu, H., Wu, F., … Fradette, S. (2022). Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 387(12), 1099–1110. https://doi.org/10.1056/nejmoa2204705
Authors:
Timothy M Miller
Merit E Cudkowicz
Angela Genge
Pamela J Shaw
Gen Sobue
Robert C Bucelli
Adriano Chiò
Philip Van Damme
Albert C Ludolph
Jonathan D Glass
Jinsy A Andrews
Suma Babu
Michael Benatar
Christopher J McDermott
Thos Cochrane
Sowmya Chary
Sheena Chew
Han Zhu
Fan Wu
Ivan Nestorov
Danielle Graham
Peng Sun
Manjit McNeill
Laura Fanning
Toby A Ferguson
Stephanie Fradette
Affiliated Authors:
Timothy M Miller
Merit E Cudkowicz
Angela Genge
Pamela J Shaw
Gen Sobue
Robert C Bucelli
Adriano Chiò
Philip Van Damme
Albert C Ludolph
Jonathan D Glass
Jinsy A Andrews
Suma Babu
Michael Benatar
Christopher J McDermott
Thos Cochrane
Sowmya Chary
Sheena Chew
Han Zhu
Fan Wu
Ivan Nestorov
Danielle Graham
Peng Sun
Manjit McNeill
Laura Fanning
Toby A Ferguson
Stephanie Fradette
Publication Type:
Article
Unique ID:
10.1056/nejmoa2204705
PMID:
Publication Date:
Data Source:
PubMed

Record Created: